A novel differential diagnosis algorithm for chronic lymphocytic leukemia using immunophenotyping with flow cytometry

Özdemi̇r, Zehra; Falay, Mesude; Parmaksiz, Ayhan; Genc, Eylem; Beyle, Ozlem; Güneş, Ahmet Kürşad; Ceran, Funda; Dağdaş, Simten; Özet, Gülsüm

doi:10.1016/j.htct.2021.08.012

Cited by 11 publications

(8 citation statements)

References 20 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As of March 2022, three new scores not included in our previous analysis have been published. [3][4][5] Their design and results align with previous efforts and examples of the above-mentioned inconsistencies can be found. For instance, Li et al 3 report CD5 sensitivity and CD43 specificity for CLL of 0.91 and 0.38, respectively, substantially different from other studies (>0.99 [6][7][8] and >0.9, 9,10 respectively), suggesting differences in cutoffs used for marker assessment (particularly for CD43), as well as in the application of the reference standard.…”

Section: Dear Editorssupporting

confidence: 71%

“…Furthermore, their score proposal includes CD20, CD200, CD45, and CD43 whilst Hoffmann et al 9 found an excellent performance by merely combining CD43 and CD200, again raising questions regarding the application of the reference standard. Finally, Ozdemir et al 4 report that 34% of B-LPD fulfil 3 of the 5 mMS criteria, 2,9,12 whilst these constitute <10% of B-LPD in most cohorts, 2,9,12 raising questions as to how points in the MS are awarded by different investigators.…”

Section: Dear Editorsmentioning

confidence: 99%

See 1 more Smart Citation

Flow cytometry in leukaemic B cell lymphoproliferative disorders. New scores, same old concerns

Sorigué

Jurado

2022

Int J Lab Hematology

View full text Add to dashboard Cite

Section: Dear Editorssupporting

confidence: 71%

Section: Dear Editorsmentioning

confidence: 99%

Flow cytometry in leukaemic B cell lymphoproliferative disorders. New scores, same old concerns

Sorigué

Jurado

2022

Int J Lab Hematology

View full text Add to dashboard Cite

“…The expression of CD81 varies significantly according to the leukemia type. CD81 expression at the surface of chronic lymphocytic leukemia (CLL) cells is dim in most cases [ 109 , 110 ]. CD81 alone is not a reliable marker to quantitate CLL cells but it is often included in a combination of markers (including for examples CD43, CD200, ROR1 and CD81) to quantify the residual disease and to optimize the identification of the CLL pathology [ 111 ].…”

Section: Regulation Of Cd81 Expression or Functions With Antibodies A...mentioning

confidence: 99%

Targeting of Tetraspanin CD81 with Monoclonal Antibodies and Small Molecules to Combat Cancers and Viral Diseases

Bailly

Thuru

2023

Cancers

View full text Add to dashboard Cite

Tetraspanin CD81 plays major roles in cell-cell interactions and the regulation of cellular trafficking. This cholesterol-embarking transmembrane protein is a co-receptor for several viruses, including HCV, HIV-1 and Chikungunya virus, which exploits the large extracellular loop EC2 for cell entry. CD81 is also an anticancer target implicated in cancer cell proliferation and mobility, and in tumor metastasis. CD81 signaling contributes to the development of solid tumors (notably colorectal, liver and gastric cancers) and has been implicated in the aggressivity of B-cell lymphomas. A variety of protein partners can interact with CD81, either to regulate attachment and uptake of viruses (HCV E2, claudin-1, IFIM1) or to contribute to tumor growth and dissemination (CD19, CD44, EWI-2). CD81-protein interactions can be modulated with molecules targeting the extracellular domain of CD81, investigated as antiviral and/or anticancer agents. Several monoclonal antibodies anti-CD81 have been developed, notably mAb 5A6 active against invasion and metastasis of triple-negative breast cancer cells. CD81-EC2 can also be targeted with natural products (trachelogenin and harzianoic acids A-B) and synthetic compounds (such as benzothiazole-quinoline derivatives). They are weak CD81 binders but offer templates for the design of new compounds targeting the open EC2 loop. There is no anti-CD81 compound in clinical development at present, but this structurally well-characterized tetraspanin warrants more substantial considerations as a drug target.

show abstract

“…Chronic lymphocytic leukemia (CLL) is among the most common leukemia in the adult population, which is characterized by persistent lymphocytosis (> 5000 clonal B cells per µL) for more than three months in peripheral blood, as proven by owcytometric analysis (1,2). The incidence of CLL has been growing worldwide, while deaths have decreased slightly (3).…”

Section: Introductionmentioning

confidence: 99%

Transformation of chronic lymphocytic leukemia into acute mixed phenotype leukemia myeloid/T neoplasm: a rare case report

Babaheidarian

Sadeghipour

Ansarinejad

et al. 2022

Preprint

View full text Add to dashboard Cite

Introduction: Chronic lymphocytic leukemia (CLL) is defined by the presence of lymphocyte in the blood, bone marrow, lymph nodes, and spleen, with a median lymphocyte count of 20–30×109/L for more than three months. CLL is known to be rarely associated with myeloid malignancies. This study presents an extremely rare case of CLL, which transformed into myeloid /T neoplasm.Case presentation: A 62-year-old man with a 10-year history of CLL was referred to our hospital because of multiple skin bruises and anemia. He was monitored for ten years without any treatment until this time when the disease progressed, and chemotherapy was started. After eight months of treatment completion, he deteriorated. This time, bone marrow biopsy immunophenotyping revealed the transformation of CLL into mixed phenotype acute leukemia, myeloid/T neoplasm with no residue of preexisting CLL.Conclusion: Transformation of CLL into acute leukemia may arise from the same clone. Still, there is some evidence that it may be therapy-related, so any deterioration in a patient with CLL should be evaluated promptly for a better outcome.

show abstract

A novel differential diagnosis algorithm for chronic lymphocytic leukemia using immunophenotyping with flow cytometry

Cited by 11 publications

References 20 publications

Flow cytometry in leukaemic B cell lymphoproliferative disorders. New scores, same old concerns

Flow cytometry in leukaemic B cell lymphoproliferative disorders. New scores, same old concerns

Targeting of Tetraspanin CD81 with Monoclonal Antibodies and Small Molecules to Combat Cancers and Viral Diseases

Transformation of chronic lymphocytic leukemia into acute mixed phenotype leukemia myeloid/T neoplasm: a rare case report

Contact Info

Product

Resources

About